Hemato Oncology Testing Global Market Is Expected To Grow At A Rate Of More Than 13% Through 2023 – 2027
22 Jun, 2023
The global hemato oncology testing market size is expected to grow from $2.79 billion in 2022 to $3.16 billion in 2023 at a compound annual growth rate (CAGR) of 13.14%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global hemato oncology testing market size is expected to reach $5.24 billion in 2027 at a CAGR of 13.53%.
Global Hemato Oncology Testing Market Key Driver
The rising incidence of hematologic cancer is likely to propel the hemato oncology testing market ahead. Hematologic malignancies are tumours that begin in the blood and affect the blood, bone marrow, and lymphatic system. These illnesses include leukaemia, lymphoma, and myeloma. These disorders can be decreased with early detection, which hemato oncology testing can provide.
Get a sample of the global hemato oncology testing market reportGlobal Hemato Oncology Testing Market Segments
The global hemato oncology testing market is segmented:
1) By Product And Services: Assay Kits And Reagents, Services
2) By Cancer Type: Leukemia, Lymphoma, Multiple Myeloma, Other Cancers
3) By Technology: Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Other Technologies
4) By End User: Hospitals, Academic And Research Institutes, Other End Users
5) By Geography: The regions covered in the hemato oncology testing market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions, North America accounts for the largest share in the global hemato oncology testing market.
Major Hemato Oncology Testing Industry Players
F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Illumina Inc., Icon plc., Invivoscribe Inc., Qiagen N.V., Bio-Rad Laboratories Inc., Archerdx Inc., Arup Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., Entrogen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc., Siemens AG
Get the full global hemato oncology testing market report
Hemato Oncology Testing Market Overview
Hemato oncology testing refers to a diagnostic test that is carried out to detect the presence of symptoms of blood disorders and blood cancers. These tests are used to diagnose anemia, infection, hemophilia, blood-clotting disorders, and leukemia.
Hemato Oncology Testing Global Market Report 2023 provides data on the global hemato oncology testing market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The hemato oncology testing market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.